22.49
-0.40%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Wuhan Hiteck Biological Pharma Co
Its shares trade on Shenzhen under the ticker 300683.SZ. It has been listed since 8 August 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥541.4m and a net loss of CN¥231.3m. At that date it held total assets of CN¥2.58bn and shareholders' equity of CN¥2.16bn.
Wuhan Hiteck Biological Pharma Co., Ltd. engages in the research, development, production, and sale of chemicals including biological products and thrombin. The company is headquartered in Wuhan, Hubei. The company went IPO on 2017-08-08. The firm operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segment’s businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Aug 2017
- Employees
- 1,346
- Website
- hiteck.com.cn ↗
Leadership
Pay as last reported
- Mr. Ya ChenChairman of the Board, General Manager
- Ms. Wen XianChief Financial Officer, Director, since 2024
- Mr. Huang ChenDeputy General Manager, Director, since 2012
- Mr. Shengqiang LiDeputy General Manager
- Mr. Kun YangSecretary of the Board
- Ms. Jie YanDirector
- Mr. Tao YangDirector
- Mr. Jiafeng ZhuDirector
- Mr. Zongfu MaoIndependent Director
- Mr. Mingdong RanIndependent Director
- Mr. Haibing ZhouIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company employs 1,346 full-time employees.
- Operates five business segments including biopharmaceuticals and medical technology services.
- Headquartered in Wuhan, Hubei with an IPO date of 2017-08-08.
Weaknesses
- No specific weaknesses mentioned in the provided information.
- No details on financial performance or market position provided.
- No information on competitive advantages or unique capabilities.
Opportunities
- Expansion in biopharmaceutical segment with primary product Jinlujie.
- Growth potential in in vitro diagnostic reagents segment.
- Potential for growth in pharmaceutical sales and wholesale segment.
Threats
- No specific threats mentioned in the provided information.
- No details on market competition or regulatory challenges provided.
- No information on economic or industry risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.